Aldeyra Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Aldeyra Therapeutics, Inc. (ALDX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ALDX insiders buying or selling?
In the last 12 months, Aldeyra Therapeutics, Inc. insiders reported 3 open-market purchases ($523.5K) and 0 sales ($0) — net buying of $523.5K. Since March 2019, Trabud has recorded 49 Form 4 filings for ALDX: 38 buys ($63.7M) and 11 sells ($11.3M).
Source: SEC EDGAR Form 4
Key Statistics (March 2019 – Jun 5, 2026)
Total Form 4 filings
49
SEC EDGAR
Insider filers
13
Insider buys (38)
$63.7M
Insider sells (11)
$11.3M
Insider sentiment
Net buyingNet insider flow of $52.4M in net buying since March 2019, and $523.5K in net buying over the last 12 months.
Recent ALDX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Todd C Brady | President and CEO | Purchase | 250.0K | $1.67 | $418.4K | SEC ↗ |
| Mar 20, 2026 | DOUGLAS RICHARD | Director | Purchase | 70.0K | $1.40 | $98.0K | SEC ↗ |
| Mar 19, 2026 | Michael Alfieri | Principal Financial Officer | Purchase | 5.0K | $1.42 | $7.1K | SEC ↗ |
| Aug 15, 2025 | Michael Alfieri | Principal Financial Officer | Purchase | 2.5K | $5.30 | $13.3K | SEC ↗ |
| Aug 13, 2025 | Stephen Machatha | Chief Development Officer | Sale | 22.1K | $5.15 | $113.7K | SEC ↗ |
| Apr 7, 2025 | Joseph Edelman | 10% Owner | Sale | 3.4M | $1.42 | $4.8M | SEC ↗ |
| Oct 22, 2024 | Nancy Miller-Rich | Director | Purchase | 922 | $11.33 | $10.4K | SEC ↗ |
| Aug 14, 2024 | Stephen Machatha | Chief Development Officer | Sale | 16.0K | $4.74 | $76.0K | SEC ↗ |
| Aug 14, 2024 | Bruce Greenberg | Interim Chief Financial Officer | Sale | 10.8K | $4.74 | $51.3K | SEC ↗ |
| Apr 17, 2024 | Stephen Machatha | Chief Development Officer | Sale | 11.5K | $3.16 | $36.5K | SEC ↗ |
| Apr 17, 2024 | Bruce Greenberg | Interim Chief Financial Officer | Sale | 13.2K | $3.41 | $45.0K | SEC ↗ |
| Apr 8, 2024 | Joseph Edelman | 10% Owner | Purchase | 178.0K | $4.68 | $833.9K | SEC ↗ |
| Apr 3, 2024 | Joseph Edelman | 10% Owner | Purchase | 504.3K | $3.84 | $1.9M | SEC ↗ |
| Mar 13, 2024 | Bruce Greenberg | Interim Chief Financial Officer | Sale | 13.2K | $3.41 | $45.0K | SEC ↗ |
| Mar 13, 2024 | Stephen Machatha | Chief Development Officer | Sale | 29.8K | $3.31 | $98.6K | SEC ↗ |
| Mar 13, 2024 | Todd C Brady | President and CEO | Sale | 183.2K | $3.17 | $580.8K | SEC ↗ |
| Oct 18, 2023 | Joseph Edelman | 10% Owner | Sale | 2.8M | $1.62 | $4.5M | SEC ↗ |
| Aug 11, 2022 | Joseph Edelman | 10% Owner | Purchase | 115.0K | $7.55 | $867.8K | SEC ↗ |
| Aug 10, 2022 | Joseph Edelman | 10% Owner | Purchase | 97.0K | $7.24 | $702.3K | SEC ↗ |
| Aug 9, 2022 | Joseph Edelman | 10% Owner | Purchase | 141.0K | $6.95 | $980.0K | SEC ↗ |
| Aug 8, 2022 | Joseph Edelman | 10% Owner | Purchase | 95.1K | $6.17 | $586.8K | SEC ↗ |
| Aug 5, 2022 | Joseph Edelman | 10% Owner | Purchase | 100.0K | $5.84 | $584.0K | SEC ↗ |
| Aug 4, 2022 | Joseph Edelman | 10% Owner | Purchase | 412.4K | $5.59 | $2.3M | SEC ↗ |
| Aug 3, 2022 | Joseph Edelman | 10% Owner | Purchase | 144.2K | $5.05 | $728.1K | SEC ↗ |
| Aug 2, 2022 | Joseph Edelman | 10% Owner | Purchase | 222.1K | $5.03 | $1.1M | SEC ↗ |
Showing the 25 most recent of 49 Form 4 filings for Aldeyra Therapeutics, Inc..
Most active ALDX insiders
- Joseph Edelman17 filings
- Todd C Brady10 filings
- DOUGLAS RICHARD5 filings
- Stephen Machatha4 filings
- Bruce Greenberg3 filings
Ask anything about ALDX insider activity
Use Trabud's AI agent to query Aldeyra Therapeutics, Inc.'s Form 4 history in plain English — "Show me ALDX CEO purchases this year" or compare it against any other ticker.
Open the AI agentALDX insider trading FAQ
Are Aldeyra Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Aldeyra Therapeutics, Inc. insiders reported 3 open-market purchases ($523.5K) and 0 sales ($0) — net buying of $523.5K. Since March 2019, Trabud has recorded 49 Form 4 filings for ALDX: 38 buys ($63.7M) and 11 sells ($11.3M). Over the full record that is net buying of $52.4M.
How many insiders trade ALDX stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Aldeyra Therapeutics, Inc.. The most recent filing was accepted on Jun 5, 2026.
Where does Trabud get ALDX insider trading data?
All ALDX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.